Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).Arun Azad, Kim N., Anthony M. Joshua et al.|Journal of Clinical Oncology|2014Cited by 7
Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).Arun Azad, Kim N., Renee Lester et al.|Journal of Clinical Oncology|2014Cited by 5
Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).Arun Azad, Kim N., Renee Lester et al.|Journal of Clinical Oncology|2014Cited by 5
Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.Laurence Albigès, Toni K. Choueiri, Bernard Escudier et al.|Journal of Clinical Oncology|2015Cited by 1